The impact of genomic changes on treatment of lung cancer

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Targeted therapies, including tyrosine kinase inhibitors (TKIs), have revolutionized advanced non-small cell lung cancer (NSCLC) treatment.
• The success of EGFR and ALK inhibitors shifted treatment paradigms from chemotherapy to molecularly tailored approaches.
• Genomic studies have identified additional actionable targets in lung adenocarcinoma.

Purpose of the Study:

• To review current oncogenic drivers in NSCLC that can be detected through genotyping.
• To highlight the therapeutic implications of these identified genomic alterations.
• To discuss practical considerations for implementing tumor genotyping in clinical decision-making for NSCLC.

Main Methods:

• Review of recent genomic studies in lung adenocarcinoma.
• Identification of potential therapeutic targets beyond EGFR and ALK.
• Discussion of clinical implications and practical aspects of tumor genotyping.

Main Results:

• EGFR mutations and ALK rearrangements are key targets for NSCLC therapy.
• Other potential targets include ROS1 rearrangements, RET fusions, MET amplification, and mutations in BRAF, HER2, and KRAS.
• These genomic alterations occur in over 1% of lung adenocarcinomas and may be targeted with existing or developing agents.

Conclusions:

• Molecularly tailored therapy is the standard of care for advanced NSCLC with identified oncogenic drivers.
• Tumor genotyping is crucial for identifying patients who can benefit from targeted therapies.
• Healthcare providers must consider tissue requirements for comprehensive genomic profiling in NSCLC diagnosis.